Auristone

Nuevocor, which has locations in both the United States and Singapore, is working on creating genetic treatments for genetic heart diseases that currently have no cure by utilizing information from our PrOSIA mechanobiology platform.

Aevice Health Pte Ltd is a Singaporean company that originated from Nanyang Technological University and focuses on tackling chronic respiratory disease. Their wearable devices allow for remote and real-time detection of heart and lung abnormalities, enabling patients to receive prompt and tailored care from home. Clinicians can also monitor patients' health and response to treatment easily through the Aevice analytical platform. Aevice Health aims to revolutionize healthcare, enhance results, and empower individuals. Visit www.aevice.com for more details.

Mirxes is a biotech firm focused on uncovering, advancing, and providing precise preventive healthcare remedies for cancer, heart-related issues, metabolic disorders, and infectious diseases. The primary objective of the company is to make diagnostic solutions that can identify diseases at an early stage globally accessible. It produces and markets highly accurate blood-based miRNA test kits for the prompt identification of cancer and various other ailments, while ensuring a non-invasive approach.

ImmunoScape is a company focused on immunomics, using a technology platform to analyze and characterize the human immune response in great detail. The Deep Immunomics platform combines various advanced techniques to provide novel and reliable immune profiling information. This technology is used in various medical fields, particularly in oncology and infectious disease, to improve understanding of immunotherapy effectiveness and safety, as well as to discover potential drug targets.

BioDefense introduces Bioshield, a product derived from edible ingredients designed to safeguard your food by enhancing its safety, freshness, and shelf life, particularly for fresh produce.

ASLAN is a pharmaceutical company that develops novel medicines for global markets. It specializes in clinical-stage immunology and oncology-focused biopharmaceuticals.

GDMC is a pharmaceutical organization that specializes in the production and development of genetic medications.

Meatiply, a company focused on food research, specializes in the creation and manufacturing of meat substitutes using cellular cultivation techniques.

Volition is a worldwide life sciences organization creating straightforward, simple to utilize blood-based malignant growth tests to analyze a scope of diseases precisely. The tests depend on the study of Nucleosomics, which is the act of distinguishing and estimating nucleosomes in the circulation system or other natural liquid which means that illness is available. As disease screening programs become an ever increasing number of far and wide, its items mean to assist with diagnosing a scope of tumors rapidly, basically, precisely, and cost-really. Early analysis can possibly draw out the existence of patients as well as to work on their personal satisfaction. Volition's innovative work exercises are right now focused in Belgium, with extra workplaces in London, Texas, and Singapore, as the organization centers around putting up its demonstrative items for sale to the public first in Europe, then, at that point, in the U.S. furthermore, around the world.

Empowering Healthier Meals by Harnessing the Best from Nature and Combining that our Knowledge of Food Science. Main product for now is Alchemy Fibre™. Available in various blends, Alchemy Fibre™ can be used with all refined carbs to help slow down glucose release and provided added fibre. Visit our website to learn more about what we do and contact us if you are interested in working with us for your F&B business/Food manufacturing business or if you just want to use Alchemy Fibre™ for home cooking situations.

Automera dedicates itself to the creation of innovative therapeutic approaches for drug development.

DotBio uses its exclusive DotBody technology to create multi-functional antibodies, which are the future of cancer treatment. These antibodies target various interactions between tumors and the tumor microenvironment in order to restore a strong immune response. Our unique technologies allow for the quick development of multi-specific antibodies that can target multiple processes. By testing combinations of these antibodies, we can quickly identify molecules that reactivate the immune response against tumors using innovative synergistic mechanisms.